دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Breakthrough COVID-19 infection in people with MS after SARS-CoV-2 vaccination: Should we still be concerned?
Zoé LE Van Kempen* and Valentina Mazziotti
doi : 10.1177/13524585231185249
Volume 29 Issue 8, July 2023
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
Susana Otero-Romero*, Christine Lebrun-Frénay* , Sa?l Reyes, Maria Pia Amato , Magda Campins, Mauricio Farez, Massimo Filippi , Yael Hacohen, Bernhard Hemmer , Rosa Juuti, Melinda Magyari , Celia Oreja-Guevara , Aksel Siva , Sandra Vukusic* and Mar Tintoré
doi : 10.1177/13524585231168043
With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy
Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
Markus Reindl and Kevin Rostasy
Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: No
Eoin P Flanagan and Patrick J Waters
Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary
Matteo Gastaldi and Diego Franciotta
Rectifying global inequities in neuromyelitis optica diagnosis and treatment
Farrah J Mateen
doi : 10.1177/13524585231179108
The standard of care for patients with neuromyelitis optica (NMO) has become highly unequal globally. Sufficient data have been published to demonstrate that NMO is a disabling�and at times, fatal�disease needing preventive immunosuppressive treatment.
Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis
Akash Virupakshaiah* , Dimitrios C Ladakis* , Bardia Nourbakhsh , Pavan Bhargava , Sonam Dilwali, Vinicius Schoeps , Kamil Borkowski, John W Newman and Emmanuelle Waubant
doi : 10.1177/13524585231171517
The circulating metabolome is altered in multiple sclerosis (MS), but its prognostic capabilities have not been extensively explored. Lipid metabolites might be of particular interest due to their multiple roles in the brain, as they can serve as structural components, energy sources, and bioactive molecules. Gaining a deeper understanding of the disease may be possible by examining the lipid metabolism in the periphery, which serves as the primary source of lipids for the brain.
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Brian G Weinshenker, Dean M Wingerchuk, Ari J Green , Jeffrey L Bennett, Ho Jin Kim , Sean J Pittock , Kazuo Fujihara, Friedemann Paul, Gary Cutter, Romain Marignier , Orhan Aktas, Hans-Peter Hartung, Dewei She, Michael Smith, William Rees, Kristina Patterson, Daniel Cimbora, Eliezer Katz * and Bruce AC Cree ; on behalf of the N-MOmentum study investigators
doi : 10.1177/13524585231172145
The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD).
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)
Kyle Smoot, Horia Marginean, Tiffany Gervasi-Follmar, Chiayi Chen , Pavle Repovic and Stanley Cohan
doi : 10.1177/13524585231175284
Natalizumab is associated with a risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients infected with John Cunningham virus (JCV). Ocrelizumab has demonstrated efficacy to treat MS; however, its safety in patients previously treated with natalizumab is unclear.
Clinical course of multiple sclerosis and patient experiences during breast cancer treatment
Alyssa N Nylander , Jessica Singh, Shane Poole, Annika Anderson, Ruth Ann Marrie , Hope Rugo and Riley Bove
doi : 10.1177/13524585231175975
Over one-third of multiple sclerosis (MS) patients are post-menopausal women, the primary demographic affected by breast cancer. After breast cancer diagnosis, there is little information about patients’ clinical experiences with both diseases.
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination
Safiya A Zaloum*, Callum H Wood*, Pooja Tank, Matthew Upcott, Nicola Vickaryous, Valerie Anderson, David Baker, Randy Chance, Nikos Evangelou , Katila George, Gavin Giovannoni, Katharine E Harding , Aimee Hibbert , Gillian Ingram, Stephen Jolles, Angray S Kang, Samantha Loveless, Stuart J Moat, Aidan Richards, Neil P Robertson, Francesca Rios, Klaus Schmierer , Mark Willis, Ruth Dobson+ and Emma C Tallantyre
doi : 10.1177/13524585231185247
People with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, the clinical consequences remain unclear.
Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2)
Sylvia Klineova* , Rebecca Straus Farber*, Tracy DeAngelis, Tungming Leung, Tyler Smith, Richard Blanck, Lana Zhovtis-Ryerson and Asaff Harel
doi : 10.1177/13524585231185246
People with MS (PwMS) and related conditions treated with anti-CD20 and S1P modulating therapies exhibit attenuated immune responses to SARS-CoV-2 vaccines. It remains unclear whether humoral/T-cell responses are valid surrogates for postvaccine immunity.
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis
Shira Simon, Ilse M Nauta , Arjan Hillebrand, Menno M Schoonheim , Bernard MJ Uitdehaag, Maureen van Dam , Hanneke E Hulst , Martin Klein, Cornelis J Stam, Brigit A de Jong and Eva MM Strijbis
doi : 10.1177/13524585231159817
Suboptimal performance during neuropsychological testing frequently occurs in multiple sclerosis (MS), leading to unreliable cognitive outcomes. Neurophysiological alterations correlate with MS-related cognitive impairment, but studies have not yet considered performance validity.
A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study
Alice M Saul , Bruce V Taylor, Leigh Blizzard, Steve Simpson-Yap , Wendy H Oddy, Nittin Shivappa, James R Hébert, Lucinda J Black, Anne-Louise Ponsonby, Simon A Broadley , Jeanette Lechner-Scott and Ingrid van der Mei; Ausimmune/AusLong Investigators Group
doi : 10.1177/13524585231167739
A pro-inflammatory diet has been posited to induce chronic inflammation within the central nervous system (CNS), and multiple sclerosis (MS) is an inflammatory disease of the CNS.
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation�A study from the neuro-urology committee of the French Association of Urology
Stéphanie Delaval, Pierre-Luc Dequirez , Claire Hentzen, Maximilien Baron, Eva Mille, François Tariel, Benoit Peyronnet, Marie-Aimée Perrouin-Verbe, Adeline Pierache , Emmanuel Chartier-Kastler, Grégoire Capon, Jean-Nicolas Cornu, Evelyne Castel-Lacanal, Xavier Gamé, Gilles Karsenty, Alain Ruffion, Pierre Denys, Alexia Even, Charles Joussain, Gérard Amarenco, Véronique Phé and Xavier Biardeau
doi : 10.1177/13524585231174580
While intravesical injections of botulinum neurotoxin A (BoNT-A) are currently recommended for patients experiencing refractory neurogenic overactive bladder and/or detrusor overactivity (OAB/DO), it is unclear how much this therapy is effective and sustainable in the long-term in patients with multiple sclerosis (MS).
Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse
Jack A Reeves*, Zachary Weinstock* , Robert Zivadinov , Michael G Dwyer, Niels Bergsland , Fahad Salman, Ferdinand Schweser, Bianca Weinstock-Guttman , Ralph HB Benedict and Dejan Jakimovski
doi : 10.1177/13524585231169466
Paramagnetic rim lesions (PRL) may be linked to relapse risk of people with relapsing–remitting multiple sclerosis (pwRRMS).
Psychometrically valid interpretation of cognitive assessments is a prerequisite for classification of cognitive phenotypes in multiple sclerosis
Joshua Sandry1, Sarah Levy2 and James F Sumowski
A taxonomic approach to cognitive diagnostics is viable and achievable in MS
Laura M Hancock1,2, Rachel Galioto3,4, Alexey Samsonov 5, Robyn M Busch3,6, Bruce Hermann1 and Jordi A Matias-Guiu
